Showing results for: Lilium News
-
Verge Genomics Named ‘Fierce 15’ Biotech for Novel Work in ALS
The treatment development company Verge Genomics — known for its all-in-human artificial intelligence platform — has been named among the “Fierce 15” by daily email newsletter Fierce Biotech. Verge’s inclusion by the web resource in the 20th annual Fierce 15 listing, announced in a company press release, acknowledges its promise as an early-stage biotechnology ...
-
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
VANCOUVER, British Columbia, – AbCellera (Nasdaq: ABCL) today announced Eli Lilly and Company (Lilly) has entered into a purchase agreement with the U.S. government to supply up to 600,000 doses, for at least $720 million, of investigational drug bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Lilly. The U.S. government will accept the ...
-
Optibrium expands operations in North America for AI and computational drug discovery technologies
Optibrium, a leading developer of software and artificial intelligence (AI) solutions for drug discovery, today announced the opening of its US subsidiary, Optibrium Inc., and the promotion of Dr Tamsin Mansley to President of the new subsidiary to lead its US-based team and business operations. The opening strengthens the Company’s direct sales, technical and application support for new ...
-
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
AbCellera (Nasdaq: ABCL) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab. The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed ...
-
New Advisory Board will guide development of CrossFire Beilstein Database
Eminent panel to steer continuing enhancement of essential chemistry and pharma research resource Frankfurt, Germany – Elsevier Information Systems GmbH, a subsidiary of Elsevier, the leading global publisher of scientific, technical and medical information, is pleased to announce the establishment of an Advisory Board with a mandate to provide recommendations on the scope, coverage, quality ...
-
Intel, General Mills, The Boston Beer Company, and partners in health win excellence awards in corporate philanthropy
Today, the Committee Encouraging Corporate Philanthropy (CECP) presents the 10th Annual Excellence Awards in Corporate Philanthropy to three corporations and one nonprofit for programs selected by an independent multidisciplinary jury according to the following criteria: demonstrated CEO leadership, dedication to measurement, successful partnerships, and innovation. This year’s ...
-
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for ...
-
Kohl`s Cares(R) scholarship program accepting nominations February 1 - March 15, ten national winners to receive $10,000 each
The Kohl's Department Stores (NYSE: KSS) Kohl's Cares Scholarship Program will award more than $415,000 in scholarships and prizes, ranging from $50 Kohl’s gift cards to $10,000 scholarships, honoring young volunteers who have made a positive impact on their communities. Nominations for kids ages six to 18 will be accepted Feb. 1 - March 15 at kohlskids.com. Kohl's enters the 11th year of ...
-
The Philhallmonic Society will perform for reach the world 2011 benefit dinner, the boathouse in Central Park, NYC; acclaimed by the press as `resounding with talent and Triumph`
The Philhallmonic Society will perform at Reach the World's 2011 Benefit Dinner at The Loeb Boathouse in Central Park, February 9, 2011. With the motto, "we sing so others can soar," The Philhallmonic Society is a unique organization under the leadership of international Broadway composer, conductor and producer Phil Hall, and is staged by Broadway dancer and choreographer Mark Santoro. ...
-
Biopharmaceutical Leaders Announce New Effort to Tackle Superbugs, Spur Development of New Antibiotics
Today more than 20 leading biopharmaceutical companies announced the creation of an estimated $1 billion fund to help support the pipeline for new antibiotic treatments. The AMR Action Fund was launched as the threat of antimicrobial resistance, or AMR, continues to grow and claim more lives. In response to today’s launch of the fund, BIO issued the following statements celebrating the ...
-
AbCellera’s statement on the neutralization activity of its monoclonal antibody therapies against the Omicron variant of concern
AbCellera and its collaborators released new preclinical data showing the pseudovirus neutralization status of its two monoclonal antibodies, bamlanivimab and bebtelovimab (also known as LY-CoV1404), against the Omicron variant. The data confirmed that the investigational antibody bebtelovimab, which is currently in Phase 2 clinical trials with our partner, Eli Lilly and Company (Lilly), ...
-
Woolsey Pharmaceuticals Completes Second Round of Financing
NEW YORK, NY – October 1, 2021 – Woolsey Pharmaceuticals announced today that it completed a second round of financing of $19.7 million. Proceeds will fund operations through the completion of Phase 2a clinical studies of BRAVYL for Wandering in Dementia, Progression Supranuclear Palsy, Corticobasal Syndrome, and Amyotrophic Lateral Sclerosis. The Company also announced the ...
-
Lumosa One of the Finalists for Clinical Advance of the Year Award in Scrip Awards 2022
We are delighted to announce that Lumosa's LT3001 (odatroltide) has been shortlisted for the "Clinical Advance of the Year Award" at this year's Pharma Intelligence Scrip Awards. This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. Other finalists include Boehringer Ingelheim and Eli Lilly's ...
-
EECO2 delivering over £10 million in global energy savings to Pharmaceutical & Life Sciences sector
Leading Energy Efficiency Consultancy EECO2 has delivered over £10 million in global energy savings to the pharmaceutical & life science sector. The energy savings are displayed on their website at www.eeco2.co.uk. The savings delivered to date amount to an astounding 252,217,127kWh and 91,564 Co2 tonnes. EECO2 have firmly established their position as a leading energy consultancy ...
-
Kohl`s department stores awards $10,000 scholarships to 10 outstanding young volunteers
Today, Kohl"s Department Stores (NYSE: KSS) named 10 outstanding young volunteers as national winners of the Kohl"s Kids Who Care Scholarship Program. As Kohl"s celebrates 10 years of rewarding stand-up kids through the program, the company has increased its 2010 national scholarship totals to $10,000 per winner. In addition to recognizing these volunteers, ranging in age from nine to 18, with ...
-
BenevolentAI To Present At The 40th Annual JP Morgan Healthcare Conference
London, 07 January, 2022BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that Joanna Shields, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January, 2022 at 8.00am ET / 13.00 GMT. About BenevolentAI BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the ...
By Benevolent
-
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data Previously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of concern Bebtelovimab binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting the potential to ...
-
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Company (“Lilly”) has declared proof of principle for the first two targets in the companies’ exclusive relationship in neurodegeneration and pain, under the companies’ global research and licensing ...
-
Dako, an Agilent Technologies Company, and Cell Signaling Technology Announce Partnership Within Companion Diagnostics
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Cell Signaling Technology (CST), a worldwide provider of antibodies, today announced that they have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products. "We are pleased to work with CST in the development of high-quality, cutting-edge companion ...
-
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed resultsfrom the Adaptive COVID-19 Treatment Trial (ACTT-2) published in the New England Journal of Medicine showed that baricitinib in combination with remdesivir reduces recovery time, improves clinical status and demonstrates a trend towards a decrease in mortality in hospitalised COVID-19 patients with pneumonia. Those who took both drugs had a median time to recovery of seven ...
By Benevolent
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you